Latest News and Press Releases

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) --   Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision...

ZUG, Sviss, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Félagið birti jákvæðar niðurstöður fyrir fasa 2b RELIEF rannsóknina á OCS-02 (licaminlimab)  sem rennir stoðum undir möguleika á fyrstu...

Dr. Klier brings significant experience in ophthalmology and drug development with a proven track record in U.S. FDA approvals, which will be instrumental as the company advances its late-stage...

ZUG, Switzerland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...

ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...

ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and...

Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior...

ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1...

ZUG, Sviss, June 10, 2024 (GLOBE NEWSWIRE) -- Virkni lyfsins var greinileg með bætingu á mörgum teiknum (e. signs) augnþurrks í öllum rannsóknarhópnum ásamt því sem aukin áhrif sáust hjá hópi...

ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company, as well as the one-time equity...